Lead investor Novo Growth has led a €22m Series A investment in The Protein Brewery, a Dutch company that is to supplement the market for protein alternatives by fungal protein.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2020-11-03_um_14.17.41.png438587Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-11-03 13:43:242020-11-03 13:43:24Protein Brewery raise €22m in Series A
Growing sector – growing guide: The 22nd edition of the Guide to German Biotech Companies has been published. Almost 120 companies from the vibrant biotech sector present themselves in the English-language yearbook.
https://european-biotechnology.com/wp-content/uploads/2024/04/ebm_Guide2020_kl.jpg540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-11-02 07:41:002024-04-02 15:51:21Best of Biotech made in Germany
https://european-biotechnology.com/wp-content/uploads/2024/04/novel-coronavirus-sars-cov-2_49680384436_o.jpg18011800Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-10-28 14:46:552020-10-28 14:46:55BI initiates Phase II testing of COVID-19 drug
https://european-biotechnology.com/wp-content/uploads/2024/04/tk04_20_PI_Candor_AP_Protector_kl2.jpg540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-10-28 11:48:352024-04-02 15:51:22AP-Protector® – Diluent for long-term storage of AP conjugates
https://european-biotechnology.com/wp-content/uploads/2024/04/3PBio.jpg11981800Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-10-28 09:28:522020-10-28 09:28:523P Bio to manufacture SpyBiotech vaccine
https://european-biotechnology.com/wp-content/uploads/2024/04/Bioinvent.png360540Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-10-28 06:03:002020-10-28 06:03:00Bioinvent AB licences BI-1206 to CASI Pharmaceuticals
Transgene SA has reported positive results of an exploratory Phase Ib/II study in HPV-16-positive cancers combining its cancer vaccine TG4001 with Merck KgaAs PD-L1 blocker avelumab.
Cell and gene therapy specialist Minaris expanding
Latest NewsJapanese CDMO Minaris Regenerative Medicine Co. Ltd will invest US$64.5m to expand its facilities in Europe and Asia.
Protein Brewery raise €22m in Series A
Latest NewsLead investor Novo Growth has led a €22m Series A investment in The Protein Brewery, a Dutch company that is to supplement the market for protein alternatives by fungal protein.
Best of Biotech made in Germany
ProductsGrowing sector – growing guide: The 22nd edition of the Guide to German Biotech Companies has been published. Almost 120 companies from the vibrant biotech sector present themselves in the English-language yearbook.
Galecto raise US$85m in Nasdaq IPO
Latest NewsHBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq.
Redx appoints new CMO
AppointmentsIn March 2021, Dr Jane Robertson will take over the position of Chief Medical Officer at Redx Pharma Plc in Alderley Park.
BI initiates Phase II testing of COVID-19 drug
Latest NewsBoehringer Ingelheim announced the start of Phase II studies of its oral TRPC6 blocker code-named BI 764198 in patients hospitalised for COVID-19.
AP-Protector® – Diluent for long-term storage of AP conjugates
ProductsAP-Protector® is a long-term stabilizer for alkaline phosphatase (AP) coupled to antibodies or Neutravidin/Streptavidin.
3P Bio to manufacture SpyBiotech vaccine
Latest NewsBritish SpyBiotech has outsourced GMP manufacturing of its VLP vaccine platform to Navarra-based 3P Biopharmaceuticals.
Bioinvent AB licences BI-1206 to CASI Pharmaceuticals
Latest NewsSwedish BioInvent AB has licensed its anti-Fc?RllB antibody BI-1206 for $95m to CASI Pharmaceuticals for distribtion in the Greater China region
Transgene reports clinical results of TG4001 plus avelumab
Latest NewsTransgene SA has reported positive results of an exploratory Phase Ib/II study in HPV-16-positive cancers combining its cancer vaccine TG4001 with Merck KgaAs PD-L1 blocker avelumab.